Category: Epidarex Portfolio News
Glasgow, United Kingdom, November 4th 2015 – Caldan Therapeutics Ltd (Caldan) has announced a £4.45 million ‘Series A’ investment led by Epidarex Capital, a leading international early-stage life science venture capital fund. Eli Lilly and Company is one of numerous limited partners in the fund….
Outstanding clinical results reported at 2015 Transcatheter Therapeutics Conference in San Francisco. Baltimore, MD, Oct. 15, 2015 – Harpoon Medical, Inc. a medical device company focused on minimally invasive mitral valve repair, announced that it has presented clinical results of ten patients enrolled in an…
By Zach Kaufman, Medgadget The device, produced by Baltimore-based Harpoon Medical, seeks to provide another in a series of recent improvements in mitral valve repair technology. While perhaps less revolutionary in form than Valtech Cardio’s Cardioband that received its CE Mark approval last week, the Harpoon…
Edinburgh, United Kingdom, 16th September, 2015 – Edinburgh Molecular Imaging Ltd. (EM Imaging) has signed an exclusive global license for a novel optical imaging agent that could improve the detection of early-stage colorectal (bowel) cancer. EM Imaging, a company which develops and commercialises novel optical imaging agents,…
The company has also received $1.4M of a $2M bridge round to accelerate its clinical program Baltimore, MD, Sept. 15, 2015 – Harpoon Medical, a medical device company focused on minimally-invasive, beating-heart, mitral valve repair, announced today that ten patients with severe degenerative mitral valve…
Edinburgh, United Kingdom, 2nd September 2015 – The Board of Edinburgh Molecular Imaging Ltd (EM Imaging) is pleased to announce the appointment of John Jeans CBE CEng as non-executive Chairman with effect from 31st August 2015. In an industrial career spanning 35 years John held…
Crestwood, KY – July 15, 2015 – Apellis Pharmaceuticals, Inc., a clinical stage complement immunotherapy company, announced today the formation of a Scientific Advisory Board (SAB) comprised of physicians and scientists recognized as key opinion leaders in the areas of immunology, pulmonology, ophthalmology and hematology….
Brighton, Sussex, May 20th 2015 – Enterprise Therapeutics Ltd, a drug discovery company focused on new therapeutics for respiratory diseases, today announced that it has secured an additional £2.4m ($3.6m) in Series-A financing. The funds are comprised of £2m by new investor, Imperial Innovations and…